^
    Back
    Association details:
    Biomarker:SMO mutation
    Cancer:Basal Cell Carcinoma
    Drug:Erivedge (vismodegib) (Hedgehog cell-signalling pathway inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    ESMO 2020
    Title:

    130P - PTCH1 Genomic Alterations (GA) in human malignancies: A pangenomic study

    Published date:
    09/14/2020
    Excerpt:
    SMO GA, which have been attributed to drug resistance in vismodegib treated pts, were exclusively identified in skin BCC samples.
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Am Acad Dermatol
    Title:

    Molecular testing in metastatic basal cell carcinoma

    Excerpt:
    Genetic analysis was conducted in 10 primary BCCs and their metastases...Four patients had SMO mutations in their tumor or metastasis, or both. All SMO mutations found were known to cause resistance to targeted therapy with vismodegib.
    DOI:
    10.1016/j.jaad.2019.12.026